Cabaletta Bio is trading at $2.25 (-10.20%) as higher crude oil prices and Treasury yields revive inflation concerns, pressuring risk assets and biotechnology valuations. - No new company-specific announcement was identified to explain the decline. - Reuters also reported shares lower during the September 23, 2026 session. - Biotech-sector strength does not appear to be supporting the stock; broad-market and risk-off sentiment are the most likely explanation.